期刊
VIRUSES-BASEL
卷 6, 期 6, 页码 2416-2427出版社
MDPI
DOI: 10.3390/v6062416
关键词
BLV; neutralizing antibody; vaccine; mimotope; HTLV-1; attenuated virus
类别
资金
- Fonds National de la Recherche Scientifique (FNRS)
- Televie
- Interuniversity Attraction Poles (IAP) Program
- Belgian Science Policy Office
- Belgian Foundation against Cancer (FBC)
- European Union [INCA LSHC-CT-2005-018704]
- Neoangio excellence program
- Partenariat Public Prive, PPP INCA of the Direction generale des Technologies, de la Recherche et de l'Energie/DG06 of the Walloon government
- Action de Recherche Concert e Glyvir (ARC) of the Communaut francaise de Belgique
- Centre anticancereux pres ULg (CAC)
- Subside Federal de Soutien a la Recherche Synbiofor and Agricultureislife projects of Gembloux Agrobiotech (GxABT)
- ULg Fonds Speciaux pour la Recherche
- Plan Cancer of the Service Public Federal
- INTA [PNSA1115054, PNBIO1131032]
- Fundacion ArgenINTA
Bovine leukemia virus (BLV) and human T-lymphotropic virus type 1 (HTLV-1) are closely related. -retroviruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e. g., HTLV-associated myelopathy/tropical spastic paraparesis) and leukemia/lymphoma (adult T-cell leukemia). Bovine leukemia virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of. -retroviruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
